Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York
MD Elliott Bennett-Guerrero, PhD Jamie L Romeiser, BS Lillian R Talbot, MD Tahmeena Ahmed, MD Linda J Mamone, MD Sunitha M Singh, PhD Janet C Hearing, MD Huda Salman, BS Dishaw D Holiprosad, BS Alex T Freedenberg, PhD Jason A Carter, BS Nicholas J Browne, PhD Megan E Cosgrove, BS Margaret E Shevik, BS Laura M Generale, BSN Margaret A Andrew, MD Sharon Nachman, MD Bettina C Fries
Critical Care Medicine, doi:10.1097/ccm.0000000000005066
OBJECTIVES: Four peer-reviewed publications have reported results from randomized controlled trials of convalescent plasma for coronavirus disease 2019 infection; none were conducted in the United States nor used standard plasma as a comparator. To determine if administration of convalescent plasma to patients with coronavirus disease 2019 increases antibodies to severe acute respiratory syndrome coronavirus 2 and improves outcome. DESIGN: Double-blind randomized controlled trial. SETTING: Hospital in New York. PATIENTS: Patients with polymerase chain reaction documented coronavirus disease 2019 infection. INTERVENTIONS: Patients were randomized (4:1) to receive 2 U of convalescent plasma versus standard plasma. Antibodies to severe acute respiratory syndrome coronavirus 2 were measured in plasma units and in trial recipients.
MEASUREMENTS AND MAIN RESULTS: Enrollment was terminated after emergency use authorization was granted for convalescent plasma. Seventy-four patients were randomized. At baseline, mean (sd) Acute Physiology and Chronic Health Evaluation II score (23.4 [5.6] and 22.5 [6.6]), percent of patients intubated (19% and 20%), and median (interquartile range) days from symptom onset to randomization of 9 (6-18) and 9 (6-15), were similar in the convalescent plasma versus standard plasma arms, respectively. Convalescent plasma had high neutralizing activity (median [interquartile range] titer 1:526 [1:359-1:786]) and its administration increased antibodies to severe acute respiratory syndrome coronavirus 2 by 14.4%, whereas standard plasma administration led to an 8.6% decrease (p = 0.005). No difference was observed for ventilator-free days through 28 days (primary study endpoint): median (interquartile range) of 28 (2-28) versus 28 (0-28; p = 0.86) for the convalescent plasma and standard plasma groups, respectively. A greater than or equal to 2 point improvement in the World Health Organization scale was achieved by 20% of subjects in both arms (p = 0.99). All-cause mortality through 90 days was numerically lower in the convalescent plasma versus standard plasma groups (27% vs 33%; p = 0.63) but did not achieve statistical significance. A key prespecified subgroup analysis of time to death in patients who were intubated at baseline was statistically significant; however, sample size numbers were small. CONCLUSIONS: Administration of convalescent plasma to hospitalized patients with coronavirus disease 2019 infection increased antibodies to severe acute respiratory syndrome coronavirus disease 2 but was not associated with improved outcome.
References
Agarwal, Mukherjee, Kumar, PLACID Trial Collaborators: Convalescent plasma in the management of moderate Covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Beigel, Aga, Mc, IRC005 Study Team: Anti-influenza immune plasma for the treatment of patients with severe influenza A: A randomised, double-blind, phase 3 trial, Lancet Respir Med
Brill, Daley, Gearwar, Generale, Halper et al., Stony Brook Medicine COVID Plasma Trial Group are as follows: Investigators: Elliott Bennett-Guerrero (Principal Investigator, Critical Care)
Carter, Freedenberg, Romeiser, Stony Brook Medicine COVID Plasma Trial Group: Impact of serological and PCR testing requirements on the selection of COVID-19 convalescent plasma donors, Transfusion
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis
Duan, Liu, Li, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci U S A
Fernando, Seshan, Pham ; Lillian, Browne, Carter et al., Plaque Reduction Neutralization Assay: Janet Hearing. Regulatory (Investigational New Drug [IND] and Institutional Review Board [IRB] support)
Freedenberg, Pan, Diehl, Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial, Transfusion
Jin, Gu, Yuan, Treatment of six COVID-19 patients with convalescent plasma, medRxiv
Joyner, Bruno, Klassen, Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients, Mayo Clin Proc
Joyner, Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19 protocol
Joyner, Senefeld, Klassen, US EAP COVID-19 Plasma Consortium: Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial threemonth experience, medRxiv
Joyner, Wright, Fairweather, Early safety indicators of COVID-19 convalescent plasma in 5000 patients, J Clin Invest
Li, Zhang, Hu, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial, JAMA
Libster, Marc, Wappner, Fundación INFANT-COVID-19 Group: Early high-titer plasma therapy to prevent severe COVID-19 in older adults, N Engl J Med
Liu, Lin, Baine, Convalescent plasma treatment of severe COVID-19: A propensity score-matched control study, Nat Med
Mair-Jenkins, Saavedra-Campos, Baillie, Convalescent Plasma Study Group: The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis, J Infect Dis
Marano, Vaglio, Pupella, Convalescent plasma: New evidence for an old therapeutic tool?, Blood Transfus
Rogers, Shehadeh, Mylona, Convalescent plasma for patients with severe COVID-19: A matched cohort study, Clin Infect Dis
Salazar, Christensen, Graviss, Treatment of COVID-19 patients with convalescent plasma reveals a signal of significantly decreased mortality, Am J Pathol
Salazar, Perez, Ashraf, Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma, Am J Pathol
Sanders, Monogue, Jodlowski, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review, JAMA
Shen, Wang, Zhao, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA
Simonovich, Pratx, Scibona, PlasmAr Study Group: A randomized trial of convalescent plasma in COVID-19 severe pneumonia, N Engl J Med
Ye, Fu, Ren, Treatment with convalescent plasma for COVID-19 patients in Wuhan, China, J Med Virol